Company Research Report: Manus Neurodynamica
Company Overview
- Name: Manus Neurodynamica Limited
- Mission: Changing the way we diagnose and monitor neuromotor impairments; making a difference today for better, faster, simpler differential diagnosis.
- Founded: 2008
- Founder: Information not provided
- Key People:
- Rutger Zietsma, CEO
- Roberto Marcucci, VP of Sales
- Dr. David Bramwell, CTO
- Phil Pattison, CFO
- Albert Nicholl, Chairman
- Keith Redpath, Non-Executive Director
- Guy Wood-Gush, Non-Executive Director
- Headquartered: 12 Alva Street, Edinburgh, EH2 4QG, United Kingdom
- Number of Employees: No information is available
- Revenue: No information is available
- Known For: The company is known for the development and commercialization of the NeuroMotor Pen™, a unique technology solution for aiding clinicians in diagnosing and monitoring neuromotor impairments such as Parkinson's Disease.
Products
NeuroMotor Pen™
- Description: A non-invasive, patented medical device that aids in the faster, earlier, and more accurate diagnosis and monitoring of neuromotor symptoms with digital record-keeping.
- Key Features:
- Sensor Technologies: Built-in highly accurate sensor technologies.
- Digital Biomarkers: Clinically validated biomarkers that quantify fine motor skills and provide objective movement abnormality data to clinicians.
- AI and Analytics: Complex analytics with AI components for supporting differential diagnosis and management of neuromotor impairments.
- Applications Beyond Parkinson’s: Utilized in screening, diagnosis, drug treatment optimization, and rehabilitation for a range of neurological disorders.
- Cloud Security: Features SmartPoints™ cybersecurity standards for data security on tablets and in the cloud.
Recent Developments
Product Launches and Features
- No new product launches were mentioned.
- Continuous enhancement of the NeuroMotor Pen™ capabilities and applications, including its use in more neurological conditions.
Partnerships and Collaborations
- Agreement with Medispa (May 5, 2023): Manus signed an agreement to integrate the NeuroMotor PenTM into the Prevention Suite used by over 10,000 pharmacies in Italy, Spain, and Portugal.
- Collaboration with Johnson & Johnson (April 24, 2023): Formation to detect neuromotor adverse effects following CAR T-cell therapy, named as an awardee in the ‘Improving Detection of Neurotoxicity in Immunotherapies’ QuickFire Challenge.
- ABHI US Accelerator 2022 Cohort Membership: Engaged in a 12-month program to leverage ABHI’s expertise and connections within the US.
Financial and Organizational Developments
- Funding Secured: £2.6 million secured to support the commercialization of the NeuroMotor PenTM as of May 25, 2023.
- Appointments of Key Personnel (June 1, 2023): Including Roberto Marcucci as VP of Sales, Dr. David Bramwell as CTO, Phil Pattison as CFO, and Albert Nicholl as Chairman.
Awards and Recognition
- Prix Galien USA 2023 Nomination: Manus was nominated in the startup category, recognizing unique contributions to patient care through innovation.
Additional Information
- Clinical Validation: Ongoing clinical trials demonstrating high accuracy and specificity in diagnosing and monitoring Parkinson's Disease.
- Certification: Manus Neurodynamica is ISO 13485 certified, ensuring top-level QMS compliance as a medical device company.
- Collaborations: Actively seeking collaborations with research institutions, clinicians, and healthcare providers to expand the applications of their technology.
Contact Information:
- Email: [info@manusneuro.com](mailto:info@manusneuro.com)
- Phone: +44 (0) 131 563 5465
- Address: 12 Alva Street, Edinburgh, EH2 4QG, United Kingdom
This report is based solely on the data provided and aims to comprehensively encapsulate the company's current scope and achievements as of the latest available information.
